Gilead Sciences announced an impending layoff at its Bay Area headquarters, as well as at its office in Seattle, and plans to close the Philadelphia facility of its subsidiary Kite Pharma.
In a Worker Adjustment and Retraining Notification (WARN) notice filed with the state of California dated November 13, Gilead specified it was cutting 104 positions at its Foster City, CA, headquarters, with an effective date of March 14, 2025. A similar WARN notification filed in Washington listed a layoff of 72 positions at Gilead's Seattle location. In both instances, the layoffs are noted as permanent. The company also announced plans to shut down the Philadelphia Kite Pharma facility in 2025.
Gilead produces several successful HIV therapies, including Biktarvy and Truvada, the COVID-19 therapy Veklury (remdesivir), as well as the chimeric antigen receptor T-cell immunotherapies Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).
In its most recent U.S. Securities and Exchange Commission filing, the firm said that its third-quarter revenue was "the strongest of the year to date" and that the company had seen 7% year-over-year revenue growth. HIV therapeutic Biktarvy showed 13% year-over-year growth, with an increase in HIV product sales of 9% over the quarter, Gilead wrote. The firm also noted a 9% increase in Veklury sales, which it attributed to increased COVID-19-related hospitalization rates, particularly in the U.S.
